Table 2.
Treatment options for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
| Lifestyle changes | Weight loss |
| Dietary changes | |
| Exercise | |
| Insulin sensitizers | Thiazolidinedione’s |
| Metformin | |
| Lipid lowering agents | Statins |
| Ezetimibe | |
| Hepatoprotective agents | UDCA |
| Antioxidants | Vitamin E |
| Incretin analogues | GLP-1 agonists |
| DPP-IV inhibitors | |
| Anti-inflammatory agents | PTX |
| Others | Probiotics |
| Angiotensin receptor blockers | |
| Endocannabinoid antagonists | |
| Bariatric surgery | |
| Liver transplantation | |
| Potential new therapeutic options | Caspases inhibitors |
| ASK1 inhibitors | |
| p38 MAPK inhibitors | |
| PPAR- alpha and delta agonists | |
| FXR agonists | |
| NOX-1/4 inhibitors | |
| Galectin-3 antagonists | |
| Acetyl CoA carboxylase inhibitors | |
| FGF-21 and FGF-19 analogues | |
| CCR2 and CCR5 inhibitors | |
| SCD-1 inhibitors | |
| Lysyl oxidase-like 2 inhibitors | |
| Sirtuins |
GLP-1: Glucagon-like peptide 1; DPP-IV: Dipeptidyl-peptidase IV; PTX: Pentoxifylline; PPAR: Peroxisome proliferator activated receptor; NOX: NADPH oxidase; FGF-21: Fibroblast growth factor 21; SCD1: Stearoyl coenzyme A desaturase 1.